Stefano Genovese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5308192/publications.pdf

Version: 2024-02-01

98 papers	6,013 citations	117625 34 h-index	71685 76 g-index
103 all docs	103 docs citations	103 times ranked	8692 citing authors

#	Article	IF	Citations
1	Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure. Cardiovascular Diabetology, 2022, 21, 51.	6.8	7
2	Changing the approach to type 2 diabetes treatment: A comparison of glucagonâ€like peptideâ€1 receptor agonists and sulphonylureas across the continuum of care. Diabetes/Metabolism Research and Reviews, 2021, 37, e3434.	4.0	5
3	Can the in-hospital mortality gap between STEMI patients with and without diabetes mellitus be reduced? The cardio-renal hypothesis. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1516-1520.	2.6	1
4	Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. Current Medical Research and Opinion, 2020, 36, 555-562.	1.9	1
5	Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus. Cardiovascular Diabetology, 2020, 19, 183.	6.8	14
6	Circulating MicroRNA-15a Associates With Retinal Damage in Patients With Early Stage Type 2 Diabetes. Frontiers in Endocrinology, 2020, 11, 254.	3.5	14
7	When Good Guys Turn Bad: Bone Marrowâ€™s and Hematopoietic Stem Cellsâ€™ Role in the Pathobiology of Diabetic Complications. International Journal of Molecular Sciences, 2020, 21, 3864.	4.1	14
8	Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality. Advances in Experimental Medicine and Biology, 2020, 1307, 153-169.	1.6	33
9	Reduced Cardio-Renal Function Accounts for Most of the In-Hospital Morbidity and Mortality Risk Among Patients With Type 2 Diabetes Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Diabetes Care, 2019, 42, 1305-1311.	8.6	15
10	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diabetes and Vascular Disease Research, 2019, 16, 399-414.	2.0	26
11	Abnormal DNA Methylation Induced by Hyperglycemia Reduces CXCR4 Gene Expression in CD34+Stem Cells. Journal of the American Heart Association, 2019, 8, e010012.	3.7	26
12	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Advances in Therapy, 2018, 35, 243-253.	2.9	19
13	Prevalence and management of diabetes in immigrants resident in the Lombardy Region: the importance of ethnicity and duration of stay. Acta Diabetologica, 2018, 55, 355-362.	2.5	8
14	Portrait of women with type 1 or type 2 diabetes of childbearing age attending diabetes clinics in Italy: the AMD-Annals initiative. Acta Diabetologica, 2018, 55, 193-199.	2.5	9
15	Generation of Human-Induced Pluripotent Stem Cells from Wolfram Syndrome Type 2 Patients Bearing the c.103â€‰+â€‰1G>A CISD2 Mutation for Disease Modeling. Stem Cells and Development, 2018, 27, 287-295.	2.1	6
16	Improved Glucose Profile in Patients With Type 2 Diabetes With a New, High-Protein, Diabetes-Specific Tube Feed During 4 Hours of Continuous Feeding. Journal of Parenteral and Enteral Nutrition, 2017, 41, 968-975.	2.6	12
17	Preclinical characterization of eleven new Cys-PEGylated hGH mutants. European Journal of Molecular and Clinical Medicine, 2017, 2, 147.	0.1	0
18	Variability in <scp>HbA1c</scp>, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1570-1578.	4.4	70

#	Article	IF	Citations
19	Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMDâ€Annals initiative. Diabetes/Metabolism Research and Reviews, 2017, 33, e2873.	4.0	26
20	Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function. Clinical Therapeutics, 2017, 39, 159-169.	2.5	19
21	Self-care, quality of life and clinical outcomes of type 2 diabetes patients: an observational cross-sectional study. Acta Diabetologica, 2017, 54, 1001-1008.	2.5	42
22	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	11.4	244
23	A rare genetic variant of BPIFB4 predisposes to high blood pressure via impairment of nitric oxide signaling. Scientific Reports, 2017, 7, 9706.	3.3	17
24	Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Scientific Reports, 2017, 7, 3313.	3.3	23
25	A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. Advances in Therapy, 2017, 34, 1791-1814.	2.9	21
26	Glycated albumin: correlation to HbA_{1c} and preliminary reference interval evaluation. Clinical Chemistry and Laboratory Medicine, 2017, 55, e31-e33.	2.3	20
27	Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 419-426.	2.3	22
28	A donor splice site mutation in CISD2 generates multiple truncated, non-functional isoforms in Wolfram syndrome type 2 patients. BMC Medical Genetics, 2017, 18, 147.	2.1	12
29	Metabolic syndrome, serum uric acid and renal risk in patients with T2D. PLoS ONE, 2017, 12, e0176058.	2.5	25
30	Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 699-710.	1.9	6
31	A unique plasma microRNA profile defines type 2 diabetes progression. PLoS ONE, 2017, 12, e0188980.	2.5	86
32	The Possible Role of Flavonoids in the Prevention of Diabetic Complications. Nutrients, 2016, 8, 310.	4.1	111
33	Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 893-898.	2.6	24
34	Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovascular Diabetology, 2016, 15, 162.	6.8	98
35	Comment on Ferrannini et al. Diabetes Care 2016;39:1108â€“1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115â€“1122. Diabetes Care, 2016, 39, e195-e195.	8.6	1
36	Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. Journal of Hypertension, 2016, 34, 2090-2098.	0.5	28

#	Article	IF	Citations
37	Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative. Diabetes Care, 2016, 39, 2278-2287.	8.6	93
38	Glucagon and heart in type 2 diabetes: new perspectives. Cardiovascular Diabetology, 2016, 15, 123.	6.8	52
39	Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?. Diabetes, Obesity and Metabolism, 2016, 18, 855-867.	4.4	57
40	The evolving frontier of diabetes therapy: The renaissance of glycemology. Diabetes Research and Clinical Practice, 2016, 118, 168-171.	2.8	3
41	Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells. Cardiovascular Diabetology, 2016, 15, 71.	6.8	66
42	Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 285-292.	2.6	86
43	Comment on Giacco et al. GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop. Diabetes 2015;64:3273â€“3284. Diabetes, 2016, 65, e5-e5.	0.6	0
44	The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes. Diabetes Research and Clinical Practice, 2016, 114, 64-68.	2.8	8
45	Atherogenicity of postprandial hyperglycemia and lipotoxicity. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 111-116.	5.7	52
46	Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 113, 179-186.	2.8	7
47	Focus on migrants with type 2 diabetes mellitus in European Countries. Internal and Emergency Medicine, 2016, 11, 319-326.	2.0	28
48	The pivotal role of high glucose-induced overexpression of PKCÎ² in the appearance of glucagon-like peptide-1 resistance in endothelial cells. Endocrine, 2016, 54, 396-410.	2.3	10
49	Economic Burden of Type 2 Diabetes Mellitus Treatment Strategies: A Cost Consequence Analysis of Sitagliptin vs Sulfonylureas in Lombardy Region. Value in Health, 2015, 18, A606.	0.3	0
50	Short-term high glucose exposure impairs insulin signaling in endothelial cells. Cardiovascular Diabetology, 2015, 14, 114.	6.8	45
51	GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress. Therapeutics and Clinical Risk Management, 2015, 11, 901.	2.0	11
52	N-Glycomic Changes in Serum Proteins in Type 2 Diabetes Mellitus Correlate with Complications and with Metabolic Syndrome Parameters. PLoS ONE, 2015, 10, e0119983.	2.5	81
53	Oscillating glucose and constant high glucose induce endoglin expression in endothelial cells: the role of oxidative stress. Acta Diabetologica, 2015, 52, 505-512.	2.5	36
54	Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?. Endocrine, 2015, 50, 56-60.	2.3	6

#	Article	IF	Citations
55	Wolfram syndrome 2: a novel CISD2 mutation identified in Italian siblings. Acta Diabetologica, 2015, 52, 175-178.	2.5	34
56	GLP-1 reduces metalloproteinase-14 and soluble endoglin induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Endocrine, 2015, 50, 508-511.	2.3	9
57	Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Therapy, 2015, 6, 239-256.	2.5	74
58	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. BMJ Open Diabetes Research and Care, 2015, 3, e000109.	2.8	7
59	Understanding EMPA-REG OUTCOME. Lancet Diabetes and Endocrinology,the, 2015, 3, 929-930.	11.4	29
60	Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy. Cardiology Journal, 2015, 22, 459-466.	1.2	9
61	Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging, 2014, 6, 771-786.	3.1	105
62	Evidences of +896 A/G TLR4 Polymorphism as an Indicative of Prevalence of Complications in T2DM Patients. Mediators of Inflammation, 2014, 2014, 1-8.	3.0	15
63	Vitamin C Further Improves the Protective Effect of Glucagon-Like Peptide-1 on Acute Hypoglycemia-Induced Oxidative Stress, Inflammation, and Endothelial Dysfunction in Type 1 Diabetes. Diabetes Care 2013;36:4104â€“4108. Diabetes Care, 2014, 37, 2063.1-2063.	8.6	0
64	Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrology Dialysis Transplantation, 2014, 29, 657-662.	0.7	49
65	The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. Cardiovascular Diabetology, 2014, 13, 140.	6.8	58
66	Nutritional imbalances linking cellular senescence and type 2 diabetes mellitus. Current Opinion in Clinical Nutrition and Metabolic Care, 2014, 17, 338-342.	2.5	4
67	Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes. Diabetes Care, 2014, 37, 1938-1943.	8.6	64
68	Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled studyâ€"the D.A.N.T.E (Diabetic ulcer Antimicrobial New) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.5	48
69	Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 116-123.	2.6	41
70	Cardiovascular guidelines: separate career may help attenuate controversy. Cardiovascular Diabetology, 2014, 13, 66.	6.8	2
71	Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes. Cardiovascular Diabetology, 2013, 12, 97.	6.8	17
72	Effects of Vildagliptin/Metformin Therapy on Patient-Reported Outcomes: Work Productivity, Patient Satisfaction, and Resource Utilization. Advances in Therapy, 2013, 30, 152-164.	2.9	20

#	Article	IF	Citations
73	Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes. Advances in Therapy, 2013, 30, 190-202.	2.9	17
74	Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes. Diabetes Care, 2013, 36, 2346-2350.	8.6	158
75	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	27.0	2,261
76	Type 1 diabetes and cardiovascular disease. Cardiovascular Diabetology, 2013, 12, 156.	6.8	81
77	Cardiovascular safety of sulfonylureas: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 938-953.	4.4	201
78	Vitamin C Further Improves the Protective Effect of Glucagon-Like Peptide-1 on Acute Hypoglycemia-Induced Oxidative Stress, Inflammation, and Endothelial Dysfunction in Type 1 Diabetes. Diabetes Care, 2013, 36, 4104-4108.	8.6	61
79	Blood Glucose Pattern Management in Diabetes: Creating Order from Disorder. Journal of Diabetes Science and Technology, 2013, 7, 1575-1584.	2.2	24
80	Centenarians as super-controls to assess the biological relevance of genetic risk factors for common age-related diseases: A proof of principle on type 2 diabetes. Aging, 2013, 5, 373-385.	3.1	57
81	Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. Journal of Endocrinological Investigation, 2013, 36, 606-16.	3.3	1
82	Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes. Results in Pharma Sciences, 2012, 2, 58-65.	4.2	15
83	Selfâ€assembling nanocomposites for protein delivery: Supramolecular interactions between PEGâ€cholane and rhâ€Gâ€CSF. Journal of Controlled Release, 2012, 162, 176-184.	9.9	24
84	Is there a relationship between factor V Leiden and type 2 diabetes?. Journal of Translational Medicine, 2009, 7, 52.	4.4	9
85	Insulinâ€Treated Type 2 Diabetes Is Associated with a Decreased Survival in Heart Failure Patients after Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1425-1432.	1.2	31
86	Clinical phenotype and Î²-cell autoimmunity in Italian patients with adult-onset diabetes. European Journal of Endocrinology, 2006, 154, 441-447.	3.7	46
87	Comparison of Capillary Electrophoresis with HPLC for Diagnosis of Factitious Hypoglycemia. Clinical Chemistry, 2000, 46, 1773-1780.	3.2	31
88	Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia, 1996, 39, 1223-1226.	6.3	84
89	The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 9412-9416.	7.1	71
90	Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia, 1995, 38, 816-822.	6.3	163

#	Article	IF	Citations
91	HLA-DQ screening for risk assessment of insulin dependent diabetes in northern Italy. Acta Diabetologica, 1995, 32, 137-142.	2.5	3
92	Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. The Clinical Investigator, 1994, 72, 494-8.	0.6	4
93	Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia, 1994, 37, 365-371.	6.3	28
94	Heterogeneous IgG Subclass Distribution of Islet Cell Antibodies. Journal of Autoimmunity, 1994, 7, 45-53.	6.5	15
95	Contribution of Glutamate Decarboxylase Antibodies to the Reactivity of Islet Cell Cytoplasmic Antibodies. Journal of Autoimmunity, 1994, 7, 497-508.	6.5	27
96	Combined analysis of IDDM-related autoantibodies in healthy schoolchildren. Lancet, The, 1994, 344, 756.	13.7	18
97	Distinct cytoplasmic islet cell antibodies with different risks for Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1992, 35, 385-388.	6.3	133
98	Novel Considerations on the Antibody/Autoantigen System in Type I (insulin-dependent) Diabetes Mellitus. Annals of Medicine, 1991, 23, 453-461.	3.8	27